Provided by Tiger Trade Technology Pte. Ltd.

Dianthus Therapeutics Inc.

106.10
-0.5200-0.49%
Volume:196.05K
Turnover:20.77M
Market Cap:5.93B
PE:-25.80
High:110.44
Open:107.69
Low:103.28
Close:106.62
52wk High:117.88
52wk Low:23.39
Shares:55.93M
Float Shares:55.85M
Volume Ratio:0.60
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1130
EPS(LYR):-4.2037
ROE:-26.07%
ROA:-17.69%
PB:5.06
PE(LYR):-25.24

Loading ...

Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise

Reuters
·
Aug 05

Dianthus Therapeutics - Reports $1.20 Bln Cash as of June 30, 2026, Provides Expected Runway into 2030

THOMSON REUTERS
·
Aug 05

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results

THOMSON REUTERS
·
Aug 05

Dianthus Therapeutics Inc Q2 Operating Expenses USD 62.243 Million

THOMSON REUTERS
·
Aug 05

Dianthus Therapeutics - Dnth312 Expected to be Phase 1 Ready by Year-End 2027

THOMSON REUTERS
·
Aug 04

Dianthus Therapeutics - Dnth312 Targets Inhibition of Ac1s and Baff/April Pathways for Autoimmune Diseases

THOMSON REUTERS
·
Aug 04

Dianthus Therapeutics - Dnth312 Demonstrates Similar Immunoglobulin Reductions to Povetacicept in Nhps

THOMSON REUTERS
·
Aug 04

Dianthus Therapeutics Inc Expected to Post a Loss of 86 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Dianthus Therapeutics Grants 87,000 Inducement Stock Options at $106.02 Per Share

Reuters
·
Aug 04

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 04

Movement Alert|Dianthus Therapeutics Rises 9.22% in Regular Trading, Trading at $104.14

Market Focus
·
Jul 18

Dianthus Therapeutics EVP, CFO and CBO Ryan Savitz Disposes of Common Shares Worth $3.06 Million

Reuters
·
Jul 14

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 06

Dianthus Therapeutics Grants 58,000 Inducement Stock Options Priced at $90.21 Per Share

Reuters
·
Jul 03

Dianthus Therapeutics - Top-line Results from Phase 3 Emerge Trial Anticipated in 2H 2028

THOMSON REUTERS
·
Jun 29

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

THOMSON REUTERS
·
Jun 29

Dianthus Therapeutics - Expects Phase 2 Momentum Trial Top-line Data in Q4 2026 and Captivate Update by Ye 2026

THOMSON REUTERS
·
Jun 29

Dianthus Therapeutics SVP, General Counsel Adam Veness disposes of USD 2.42 million in common shares

Reuters
·
Jun 19

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Jun 17

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Dianthus Therapeutics (DNTH)

TIPRANKS
·
Jun 15